The P/E ratio measures how cheaply valued a company’s stock price is by dividing the current stock price to its earnings-per-share (EPS). It indicates the dollar amount an investor can expect to invest in a company to receive $1 of that company’s earnings. Maravai LifeSciences Holdings P/E ratio is 16.29. it has decreased in comparison to the same period last year. this metric is one of the most popular because it easily summarizes the status of the company. however, in order to make an informed decision, more metrics should be analysed. Let’s dive into Maravai LifeSciences Holdings’s P/E ratio
What is Maravai LifeSciences Holdings P/E Ratio?
The P/E ratio of Maravai LifeSciences Holdings is 16.29, which represents a 31.7% decrease from the same period last year. their average P/E ratio is 21.78 and their 5-year average is 23.94.
What is Maravai LifeSciences Holdings Net EPS?
Maravai LifeSciences Holdings’s net earnings for the last quarter were 1.72 US dollars, which represents a 19.44% increase over the same period last year.
Who are Maravai LifeSciences Holdings Competitors?
Based on Jika.io AI model, CStone Pharmaceuticals, Abcam, Alnylam Pharmaceuticals, ArcticZymes Technologies ASA, Blueprint Medicines, Idorsia, Ultragenyx Pharmaceutical, Bio-Techne are considered to be Maravai LifeSciences Holdings’s competitors because the companies operate within the same industry as Maravai LifeSciences Holdings and are targeting the same customer base. in addition, competitors typically share a similar market capitalization as Maravai LifeSciences Holdings.
Who is Maravai LifeSciences Holdings’s Biggest competitor?
Maravai LifeSciences Holdings’s biggest competitor is CStone Pharmaceuticals, based on the Jika.io AI model. it has a similar market capitalization to Maravai LifeSciences Holdings in the industry, it dominates a similar share of the market as Maravai LifeSciences Holdings, and it provides and markets very similar services.
What industry is Maravai LifeSciences Holdings in?
Maravai LifeSciences Holdings is part of the Biotechnology and Healthcare sectors.
Maravai LifeSciences Holdings vs CStone Pharmaceuticals
Market Cap: Maravai LifeSciences Holdings’s Market Cap of 7146051072 is higher than CStone Pharmaceuticals Market Cap of 6232379904.
Average Volume: Maravai LifeSciences Holdings’s Average Volume of 1.502M is higher than CStone Pharmaceuticals Average Volume of 1.119M.
Beta: Maravai LifeSciences Holdings’s Beta of 0.0 is lower than CStone Pharmaceuticals Beta of 0.01.
Revenue: Maravai LifeSciences Holdings’s Revenue of 799.24M is higher than CStone Pharmaceuticals Revenue of 243.718M.
Net Income: Maravai LifeSciences Holdings’s Net Income of 182.037M is higher than CStone Pharmaceuticals Net Income of -1.92B.
Gross Profit: Maravai LifeSciences Holdings’s Gross Profit of 658.679M is higher than CStone Pharmaceuticals Gross Profit of 136.886M.
Ebitda: Maravai LifeSciences Holdings’s Ebitda of 298.564M is higher than CStone Pharmaceuticals Ebitda of -1.895B.
P/E Ratio: Maravai LifeSciences Holdings’s P/E Ratio of 15.73 is higher than CStone Pharmaceuticals P/E Ratio of -5.7.
P/B Ratio: Maravai LifeSciences Holdings’s P/B Ratio of 9.62 is higher than CStone Pharmaceuticals P/B Ratio of 5.15.
P/FCF Ratio: Maravai LifeSciences Holdings’s P/FCF Ratio of 7.7 is higher than CStone Pharmaceuticals P/FCF Ratio of -16.67.
ROE: Maravai LifeSciences Holdings’s ROE of 0.67 is higher than CStone Pharmaceuticals ROE of -0.52.
ROA: Maravai LifeSciences Holdings’s ROA of 0.11 is higher than CStone Pharmaceuticals ROA of -0.48.
Return On Capital Employed: Maravai LifeSciences Holdings’s Return On Capital Employed of 0.32 is higher than CStone Pharmaceuticals Return On Capital Employed of -0.42.
Assets (Total): Maravai LifeSciences Holdings’s Assets (Total) of 1.918B is lower than CStone Pharmaceuticals Assets (Total) of 2.271B.
Debt (Total): Maravai LifeSciences Holdings’s Debt (Total) of 534.313M is higher than CStone Pharmaceuticals Debt (Total) of 174.198M.
Shareholders Equity: Maravai LifeSciences Holdings’s Shareholders Equity of 315.499M is higher than CStone Pharmaceuticals Shareholders Equity of 1.207B.
Maravai LifeSciences Holdings vs Abcam
Market Cap: Maravai LifeSciences Holdings’s Market Cap of 7146051072 is higher than Abcam Market Cap of 3305980160.
Average Volume: Maravai LifeSciences Holdings’s Average Volume of 1.502M is lower than Abcam Average Volume of 127074.0.
Beta: Maravai LifeSciences Holdings’s Beta of 0.0 is lower than Abcam Beta of 0.71.
Revenue: Maravai LifeSciences Holdings’s Revenue of 799.24M is higher than Abcam Revenue of 297.7M.
Net Income: Maravai LifeSciences Holdings’s Net Income of 182.037M is higher than Abcam Net Income of 16.2M.
Gross Profit: Maravai LifeSciences Holdings’s Gross Profit of 658.679M is higher than Abcam Gross Profit of 211.8M.
Ebitda: Maravai LifeSciences Holdings’s Ebitda of 298.564M is lower than Abcam Ebitda of 64.0M.
P/E Ratio: Maravai LifeSciences Holdings’s P/E Ratio of 15.73 is lower than Abcam P/E Ratio of 180.5.
P/S Ratio: Maravai LifeSciences Holdings’s P/S Ratio of 4.11 is lower than Abcam P/S Ratio of 8.42.
P/B Ratio: Maravai LifeSciences Holdings’s P/B Ratio of 9.62 is higher than Abcam P/B Ratio of 3.34.
P/FCF Ratio: Maravai LifeSciences Holdings’s P/FCF Ratio of 7.7 is lower than Abcam P/FCF Ratio of 80.16.
ROE: Maravai LifeSciences Holdings’s ROE of 0.67 is higher than Abcam ROE of 0.02.
ROA: Maravai LifeSciences Holdings’s ROA of 0.11 is higher than Abcam ROA of 0.01.
Return On Capital Employed: Maravai LifeSciences Holdings’s Return On Capital Employed of 0.32 is higher than Abcam Return On Capital Employed of 0.01.
Gross Profit Margin: Maravai LifeSciences Holdings’s Gross Profit Margin of 0.83 is higher than Abcam Gross Profit Margin of 0.69.
Assets (Total): Maravai LifeSciences Holdings’s Assets (Total) of 1.918B is lower than Abcam Assets (Total) of 811.4M.
Debt (Total): Maravai LifeSciences Holdings’s Debt (Total) of 534.313M is higher than Abcam Debt (Total) of 234.2M.
Maravai LifeSciences Holdings vs Alnylam Pharmaceuticals
Market Cap: Maravai LifeSciences Holdings’s Market Cap of 7146051072 is lower than Alnylam Pharmaceuticals Market Cap of 18122100736.
Average Volume: Maravai LifeSciences Holdings’s Average Volume of 1.502M is lower than Alnylam Pharmaceuticals Average Volume of 887995.0.
Beta: Maravai LifeSciences Holdings’s Beta of 0.0 is lower than Alnylam Pharmaceuticals Beta of 0.94.
Revenue: Maravai LifeSciences Holdings’s Revenue of 799.24M is lower than Alnylam Pharmaceuticals Revenue of 844.287M.
Net Income: Maravai LifeSciences Holdings’s Net Income of 182.037M is higher than Alnylam Pharmaceuticals Net Income of -852.824M.
Gross Profit: Maravai LifeSciences Holdings’s Gross Profit of 658.679M is lower than Alnylam Pharmaceuticals Gross Profit of 704.143M.
Ebitda: Maravai LifeSciences Holdings’s Ebitda of 298.564M is higher than Alnylam Pharmaceuticals Ebitda of -948.958M.
P/E Ratio: Maravai LifeSciences Holdings’s P/E Ratio of 15.73 is higher than Alnylam Pharmaceuticals P/E Ratio of -20.12.
P/S Ratio: Maravai LifeSciences Holdings’s P/S Ratio of 4.11 is higher than Alnylam Pharmaceuticals P/S Ratio of 20.42.
P/B Ratio: Maravai LifeSciences Holdings’s P/B Ratio of 9.62 is higher than Alnylam Pharmaceuticals P/B Ratio of 44.78.
P/FCF Ratio: Maravai LifeSciences Holdings’s P/FCF Ratio of 7.7 is higher than Alnylam Pharmaceuticals P/FCF Ratio of -31.84.
ROE: Maravai LifeSciences Holdings’s ROE of 0.67 is higher than Alnylam Pharmaceuticals ROE of -1.37.
ROA: Maravai LifeSciences Holdings’s ROA of 0.11 is higher than Alnylam Pharmaceuticals ROA of -0.26.
Return On Capital Employed: Maravai LifeSciences Holdings’s Return On Capital Employed of 0.32 is higher than Alnylam Pharmaceuticals Return On Capital Employed of -0.24.
Gross Profit Margin: Maravai LifeSciences Holdings’s Gross Profit Margin of 0.83 is lower than Alnylam Pharmaceuticals Gross Profit Margin of 0.84.
Assets (Total): Maravai LifeSciences Holdings’s Assets (Total) of 1.918B is lower than Alnylam Pharmaceuticals Assets (Total) of 3.643B.
Maravai LifeSciences Holdings vs ArcticZymes Technologies ASA
Market Cap: Maravai LifeSciences Holdings’s Market Cap of 7146051072 is higher than ArcticZymes Technologies ASA Market Cap of 3974303488.
Average Volume: Maravai LifeSciences Holdings’s Average Volume of 1.502M is lower than ArcticZymes Technologies ASA Average Volume of 86089.0.
Beta: Maravai LifeSciences Holdings’s Beta of 0.0 is lower than ArcticZymes Technologies ASA Beta of 1.81.
Revenue: Maravai LifeSciences Holdings’s Revenue of 799.24M is higher than ArcticZymes Technologies ASA Revenue of 127.97M.
Net Income: Maravai LifeSciences Holdings’s Net Income of 182.037M is lower than ArcticZymes Technologies ASA Net Income of 46.38M.
Gross Profit: Maravai LifeSciences Holdings’s Gross Profit of 658.679M is higher than ArcticZymes Technologies ASA Gross Profit of 124.085M.
Ebitda: Maravai LifeSciences Holdings’s Ebitda of 298.564M is lower than ArcticZymes Technologies ASA Ebitda of 62.886M.
P/E Ratio: Maravai LifeSciences Holdings’s P/E Ratio of 15.73 is lower than ArcticZymes Technologies ASA P/E Ratio of 85.76.
P/S Ratio: Maravai LifeSciences Holdings’s P/S Ratio of 4.11 is higher than ArcticZymes Technologies ASA P/S Ratio of 28.81.
P/B Ratio: Maravai LifeSciences Holdings’s P/B Ratio of 9.62 is higher than ArcticZymes Technologies ASA P/B Ratio of 15.05.
P/FCF Ratio: Maravai LifeSciences Holdings’s P/FCF Ratio of 7.7 is higher than ArcticZymes Technologies ASA P/FCF Ratio of 64.48.
ROE: Maravai LifeSciences Holdings’s ROE of 0.67 is higher than ArcticZymes Technologies ASA ROE of 0.22.
ROA: Maravai LifeSciences Holdings’s ROA of 0.11 is lower than ArcticZymes Technologies ASA ROA of 0.18.
Return On Capital Employed: Maravai LifeSciences Holdings’s Return On Capital Employed of 0.32 is higher than ArcticZymes Technologies ASA Return On Capital Employed of 0.23.
Gross Profit Margin: Maravai LifeSciences Holdings’s Gross Profit Margin of 0.83 is lower than ArcticZymes Technologies ASA Gross Profit Margin of 0.97.
About Maravai LifeSciences Holdings
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases in the United States and internationally. the company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibodies for the detection of impurities during the production of biopharmaceutical products and products for the detection of protein expression in tissues of different species. it operates in two segments, Nucleic Acid Production and Biologics Safety Testing. the Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy and molecular diagnostics, including reagents used in chemical synthesis, modification, labelling and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). this segment also offers messenger RNA, oligonucleotides and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. the Biologics Safety Testing segment sells analytical products for use in the development of biologic manufacturing processes, including custom product-specific development antibodies and assay development services. this segment also provides HCP ELISA kits, other bioprocess impurities and contaminant ELISA kits, ancillary reagents and custom services. the company serves biopharmaceutical companies and other biopharmaceutical and life sciences research companies, and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2020 and is headquartered in San Diego, California.
